Developing streamlined, flexible cell therapy process workflows: from upstream to formulation and fill-finish operations

Wednesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET

Sponsor

Developing streamlined, flexible cell therapy process workflows: from upstream to formulation and fill-finish operations

Recent advances in engineered cell therapy are creating demand for flexible, closed, and automated systems that can adapt to both autologous and allogeneic workflows while ensuring consistency and GMP compliance.

Attend this webinar for expert review and discussion of current and emerging closed, modular cell therapy process workflows and instrumentation, from upstream technologies supporting cell isolation, transfection, and genome engineering to a quick dive into formulation and fill-finish operations. Case study data relevant to CAR-T, CAR-NK, and CAR-iPSC workflows will be presented, demonstrating the integration of upstream and downstream processes and the acceleration of cell therapy manufacturing from discovery through commercial scale. Last but not least, attendees will receive an exclusive preview of performance data for the Gibco™ CTS™ Compleo™ Fill and Finish System.

Attend this webinar to learn how to:

• Streamline and de-risk manufacturing workflows with closed modular instruments

• Improve the reliability and reproducibility of genome engineering workflows

• Identify and harness key process control and flexibility benefits for advanced therapy process development while maintaining scalability across diverse cell types

• Simplify cell processing and maintain high levels of cell recovery and viability

• Improve accuracy and reproducibility while simplifying formulation and fill-finish operations

Namritha Ravinder

Director R&D, Cell and Gene Therapy Platforms at Thermo Fisher Scientific

Having earned a doctorate degree in Biotechnology from University of Alabama in Huntsville and completed a post-doctoral fellowship in HIV Virology from Children’s Hospital in Los Angeles, Namritha joined Thermo Fisher Scientific in 2008. There she led several custom service offerings including cDNA library synthesis, RNAi screening, mRNA service, virus production, and cell engineering before leading a product development team focused on gene editing and modulation. In her current role, Namritha manages an R&D group dedicated to developing automated instrument platforms to address cell processing, gene delivery, and cell engineering needs within cell and gene therapy workflows.

Carl Dargitz

Senior R&D Manger, Cell and Gene Therapy Platforms at Thermo Fisher Scientific

Carl Dargitz’s team led the development the Gibco™ CTS™ Rotea™ Counterflow Centrifugation System and the soon to be released Gibco™ CTS™ Compleo™ Fill and Finish System. Previously, he developed reprogramming and characterization assays for PSCs and immune cells at Thermo Fisher. Before joining Thermo Fisher, he worked at the Salk Institute for Biological Studies at the stem cell core facility managing the core’s reprogramming and characterization services. He received his M.S. from California Polytechnic State University, San Luis Obispo in Biomedical Engineering with a specialization in stem cell research in 2013.

In 45 Days

You have registered for this webinar